12/20
06:40 am
smmt
Where Will Summit Therapeutics Be in 5 Years? [Yahoo! Finance]
Low
Report
Where Will Summit Therapeutics Be in 5 Years? [Yahoo! Finance]
12/20
05:00 am
smmt
3 Stocks That Could Turn $1,000 into $5,000 by 2030 [Yahoo! Finance]
Low
Report
3 Stocks That Could Turn $1,000 into $5,000 by 2030 [Yahoo! Finance]
12/13
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/11
09:04 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
12/9
09:56 am
smmt
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday [Yahoo! Finance]
Low
Report
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday [Yahoo! Finance]
12/6
08:45 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $31.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $31.00 price target on the stock.
11/30
06:13 am
smmt
Warning: This Skyrocketing Stock Has a Hidden Risk [Yahoo! Finance]
Low
Report
Warning: This Skyrocketing Stock Has a Hidden Risk [Yahoo! Finance]
11/26
04:15 pm
smmt
Summit Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Summit Therapeutics to Present at Upcoming Investor Conferences
11/21
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/20
08:47 am
smmt
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why [Yahoo! Finance]
11/18
08:07 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
11/18
07:34 am
smmt
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]
11/9
02:21 pm
smmt
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]
Low
Report
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]
11/4
07:11 pm
smmt
Why Summit Therapeutics Stock Was a Winner Today [Yahoo! Finance]
Low
Report
Why Summit Therapeutics Stock Was a Winner Today [Yahoo! Finance]
11/4
01:56 pm
smmt
Summit Therapeutics Leads the Parade of Big Gainers [Yahoo! Finance]
Low
Report
Summit Therapeutics Leads the Parade of Big Gainers [Yahoo! Finance]
11/4
09:17 am
smmt
Summit Therapeutics Leads The Parade Of Big Gainers [Forbes]
Medium
Report
Summit Therapeutics Leads The Parade Of Big Gainers [Forbes]
11/4
08:19 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $32.00 price target on the stock.
10/31
10:45 pm
smmt
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab [Yahoo! Finance]
Low
Report
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab [Yahoo! Finance]
10/31
08:35 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its price target lowered by analysts at HC Wainwright from $45.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its price target lowered by analysts at HC Wainwright from $45.00 to $44.00. They now have a "buy" rating on the stock.
10/30
07:00 am
smmt
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
High
Report
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
10/27
02:37 pm
smmt
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
Medium
Report
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
10/27
09:27 am
smmt
Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer [Yahoo! Finance]
Medium
Report
Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer [Yahoo! Finance]
10/24
05:23 am
smmt
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? [Yahoo! Finance]
Low
Report
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? [Yahoo! Finance]
10/23
04:15 pm
smmt
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
Medium
Report
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024